Ceftriaxone
| 證據等級: L5 | 預測適應症: 7 個 |
目錄
CEFTRIAXONE: From Bacterial Infections to Hyperamylasemia
One-Sentence Summary
Ceftriaxone is a third-generation cephalosporin antibiotic widely used for treating serious bacterial infections including meningitis, pneumonia, and sepsis. The TxGNN model predicts it may have utility in Hyperamylasemia, with 0 clinical trials and 3 publications currently supporting this direction — all via indirect mechanistic links rather than direct therapeutic evidence. At Evidence Level L4, this prediction warrants a Hold decision pending mechanistic clarification.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Serious bacterial infections (not registered in New Zealand) |
| Predicted New Indication | Hyperamylasemia |
| TxGNN Prediction Score | 99.39% |
| Evidence Level | L4 |
| New Zealand Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available from the Evidence Pack. Based on established pharmacological knowledge, ceftriaxone is a third-generation cephalosporin beta-lactam antibiotic. It exerts its bactericidal effect by binding to penicillin-binding proteins (PBPs) and inhibiting bacterial cell wall synthesis, leading to cell lysis. Its long half-life (6–9 hours) permits once-daily dosing, and its broad spectrum covers gram-positive organisms (including penicillin-resistant Streptococcus pneumoniae) and many gram-negative pathogens.
The connection between ceftriaxone and hyperamylasemia is not a direct therapeutic one. The mechanistic link is indirect and operates through two pathways: first, leptospirosis (Weil's syndrome) is a known cause of secondary hyperamylasemia, and ceftriaxone is the drug of choice for treating leptospirosis — treating the underlying infection may resolve the associated enzyme elevation. Second, prophylactic ceftriaxone administered after endoscopic papillosphincterotomy (EPS) may prevent secondary biliary infections, thereby reducing post-procedural pancreatic enzyme elevation.
These relationships represent coincidental or secondary effects rather than a direct mechanism for treating hyperamylasemia per se. The high TxGNN score (99.39%) most likely reflects disease co-occurrence patterns in the knowledge graph — specifically, the shared nodes between infectious disease entities and pancreatic enzyme abnormalities — rather than a genuine repurposing signal. Further mechanistic hypothesis generation is needed before this candidate can advance.
Clinical Trial Evidence
Currently no related clinical trials registered for ceftriaxone in hyperamylasemia.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 10458061 | 1999 | RCT/Observational | Bratislavske lekarske listy | Prophylactic ceftriaxone 1 g in 30 patients after endoscopic papillosphincterotomy and gallstone extraction; compared with controls without prophylaxis. Most common bile isolates were Pseudomonas aeruginosa and E. coli, all sensitive to ceftriaxone. Prophylactic effect on post-procedural biliary/pancreatic enzyme changes was assessed. |
| 7522351 | 1994 | Observational | Southern Medical Journal | Evaluated elevated pancreatic amylase and lipase in 38 patients with intracranial bleeding without pancreatitis; 25 had elevated lipase, 17/25 also had elevated amylase. Describes hyperamylasemia as a neurogenic phenomenon unrelated to antibiotic therapy. |
| 36263834 | 2023 | Case Report | Revista española de enfermedades digestivas | Weil syndrome (leptospirosis) presenting with upper GI bleeding; demonstrates that leptospirosis — for which ceftriaxone is first-line treatment — can cause multi-organ involvement including pancreatic enzyme elevation. Ceftriaxone not directly evaluated for hyperamylasemia. |
New Zealand Market Information
Ceftriaxone has no registered product authorizations in New Zealand based on the current Evidence Pack data.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The three retrieved publications link ceftriaxone to hyperamylasemia only through indirect mechanisms — treating an underlying infection (leptospirosis) or preventing post-procedural biliary complications — with no study directly evaluating ceftriaxone as a therapy for hyperamylasemia itself. The TxGNN signal most likely reflects knowledge graph co-occurrence rather than a repurposing-actionable therapeutic relationship.
To proceed, the following is needed:
- A coherent mechanistic hypothesis explaining how ceftriaxone could directly modulate serum amylase levels, independent of infection treatment
- Preclinical data (in vitro or animal models) demonstrating any direct effect on pancreatic acinar cell function or amylase secretion
- A systematic literature review to determine whether any population receiving ceftriaxone has shown measurable amylase reduction as a primary outcome
- Clarification of ceftriaxone's full MOA profile (DrugBank data) to identify any off-target effects relevant to pancreatic physiology
- Regulatory baseline: obtain package insert warnings and contraindications before any clinical exploration
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.